253 related articles for article (PubMed ID: 36493559)
1. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C
Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcalá C; Quintanilla-Bordás C; Gascón F; Sempere ÁP; Navarro L; Carcelén-Gadea M; Landete L; Mallada J; Cañizares E; Belenguer A; Carratalá S; Domínguez JA; Pérez-Miralles FC; Gil-Perotín S; Gasqué R; Cubas L; Castillo J; Casanova B
J Neurol; 2022 Jul; 269(7):3676-3681. PubMed ID: 35107597
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
[TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
Cellerino M; Boffa G; Lapucci C; Tazza F; Sbragia E; Mancuso E; Bruschi N; Minguzzi S; Ivaldi F; Poirè I; Laroni A; Mancardi G; Capello E; Uccelli A; Novi G; Inglese M
Neurotherapeutics; 2021 Oct; 18(4):2579-2588. PubMed ID: 34553320
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
[TBL] [Abstract][Full Text] [Related]
9. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
[TBL] [Abstract][Full Text] [Related]
11. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
[TBL] [Abstract][Full Text] [Related]
14. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I; Hughes S; McDonnell G; Malpas CB; Sharmin S; Boz C; Alroughani R; Ozakbas S; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Lechner-Scott J; Kuhle J; Terzi M; Laureys G; Van Hijfte L; John N; Grammond P; Grand'Maison F; Soysal A; Jensen AV; Rasmussen PV; Svendsen KB; Barzinji I; Nielsen HH; Sejbæk T; Prakash S; Stilund MLM; Weglewski A; Issa NM; Kant M; Sellebjerg F; Gray O; Magyari M; Kalincik T;
JAMA Neurol; 2023 Aug; 80(8):789-797. PubMed ID: 37307006
[TBL] [Abstract][Full Text] [Related]
15. Real world study of ocrelizumab in multiple sclerosis: Kuwait experience.
Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
Mult Scler Relat Disord; 2023 Nov; 79():104941. PubMed ID: 37633033
[TBL] [Abstract][Full Text] [Related]
16. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
[TBL] [Abstract][Full Text] [Related]
17. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Stahnke AM; Holt KM
Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
